Neuronet - Efficiently Networking European Neurodegeneration Research

          Newsletter 4 - June 30, 2020

Welcome to the fourth
issue of the Neuronet newsletter! 

We hope this newsletter finds you well. This fourth newsletter issue provides you with up-to-date insights on the Innovative Medicines Initiative’s (IMI) research efforts to tackle challenges in neurodegeneration. Our programme actively connects 17 research projects. We are happy to welcome the Mobilise-D project, which has recently joined the Neuronet programme. Mobilise-D aims to develop a comprehensive system to analyse people’s gait based on digital technologies and is focusing on conditions which often affect mobility such as Parkinson’s disease and multiple sclerosis.

We are delighted, as ever, to share the progress we are making with Neuronet. There are many highlights including the finalisation of the first version of an ‘asset map’ that depicts the richness of the IMI Neurodegeneration portfolio in terms of tools and results in a consolidated way. Our Working Groups have also been busy, holding online meetings and finalising deliverable reports that form first drafts of guidance on data sharing, patient privacy and sustainability. At the beginning of June we held a very engaging online Scientific Coordination Board meeting. 10 IMI projects were represented at the meeting and a key topic was COVID-19 and the impact the pandemic is having on the IMI Neurodegeneration projects.  Project leaders discussed how the Europe-wide lockdown measures have impacted on project activities and collaborators.

An important date for your calendars: the annual Neuronet event will now be held online, during the 30th Alzheimer Europe Conference between 20-22 October. Originally planned to take place in Bucharest, the virtual conference is being held under the banner “Dementia in a changing world”. Several Neuronet parallel sessions will be held where we will highlight the IMI neurodegeneration projects. More details about the Neuronet event will be available on our website as soon as matters are finalised.

As always, this newsletter also provides you with updates on progress and achievements from the IMI neurodegeneration research projects. Last but not least, we'd like to highlight that this issue also features a spotlight on early-career investigators. We spoke to Sarah Gregory who told us about her work on the EPAD project.

Happy reading and stay safe!
Carlos Díaz
Neuronet Project Coordinator
Research Management Partners
Lennert Steukers
Neuronet Project Leader
Associate Director,
Clinical Scientist, Janssen Pharmaceutica NV



Spotlight on early-career investigators: a Neuronet interview with Sarah Gregory

Attending the Scottish EPAD Participant Panel is one of the highlights of my role within EPAD. The panels were set up as the major method for participants to contribute to the ongoing running of the study. The panel meetings are participant led with staff attending to support with logistics, such as room booking and minuting, as well provide any study updates and ensure topics discussed in the panels are actioned within the study.
Read more

Neuronet holds an online Scientific Coordination Board meeting

On Friday 5 June, Neuronet convened an online meeting of its Scientific Coordination Board (SCB). This was the fourth meeting of the SCB, which is composed of 16 leaders from Innovative Medicines Initiative (IMI) projects on neurodegeneration.  10 IMI projects were represented at the SCB meeting, which was also attended by Neuronet consortium members
Read more

New perspectives in Alzheimer’s research – Scalable culturing technique for stem cell models developed

LIFE & BRAIN GmbH, a SME based in Bonn, Germany, and partner within the PHAGO consortium, has filed a patent application with the EPO (European Patent Office) on an improved protocol for the large-scale derivation of human microglia from induced pluripotent stem cells (iPSCs). Researchers within PHAGO, a pan-European project funded by the Innovative Medicines Initiative (IMI), look at genetically distinct iPSCs generated from the blood of AD patients and microglia derived from them.
Read more

EPAD V1500.0 dataset is now available to the entire research community

The European Prevention of Alzheimer’s Dementia (EPAD) project is very pleased to announce the external release of its second wave of data including the baseline data from the first 1.500 research participants (V1500.0).
Read more

Development of the digital RADAR-BASE platform within the framework of RADAR-AD and RADAR-CNS

The RADAR-base platform is an end-to-end solution to collect, manage and store sensor data from smartphones and wearable devices to enable remote monitoring of study participants and decentralized clinical trials. The platform supports multiple devices and can be used for a range of disease areas as its modular plugin-based architecture allows for simple and fast extension and customization.
Read more

Fraunhofer SCAI launches a new COVID-19 knowledge space, building on tools developed during the AETIONOMY & PHAGO projects

On 23 April, Fraunhofer SCAI launched a new COVID-19 knowledge space which hosts tools for information extraction and literature mining, as well as SARS-CoV-2 disease models and information on chemical compounds and approved drugs that may be effective against SARS-CoV-2, the coronavirus that causes COVID-19.
Read more

Job Opportunity


VUmc is recruiting a Clinical Trial Manager for the AMYPAD project

The Amsterdam UMC location VUmc is recruiting a Clinical Trial Manager to support the Sponsor in ensuring good conduct of the AMYPAD Prognostic and Natural History Study (PNHS) across participating sites. This study involves 17 sites in 8 countries across Europe. Apply before 8 July 2020!
Read more



Mark the dates!

Neuronet's annual networking and communication event will highlight Innovative Medicine Initiative projects that work in the area of neurodegeneration research. The event will take place at the Alzheimer Europe Conference. More information will follow in due time!

Neuronet project newsletters

RADAR-AD - Remote assessment of disease and relapse – Alzheimer’s disease
June 2020 (RADAR-AD)
This newsletter provides you with the latest updates from the RADAR-AD project including the ethics interviews held by RADAR-AD members with patients and carers from the Patient Advisory Board (PAB) and the first site initiation visit conducted in February.
Amyloid imaging to prevent Alzheimer's disease Newsletter
June 2020 (AMYPAD)
In this issue, you will find a spotlight on the AMYPAD WP2, interviews with two AMYPAD collaborators, the highlighted achievements over the past quarter as well as AMYPAD’s participation in relevant events.
European Prevention of Alzheimer's Dementia Newsletter
May 2020 (EPAD)
Find out about the highlights of Q1 2020, the PhD defence of two EPAD fellows and read about project insights in two interviews with project partners.
European Quality In Preclinical Data Newsletter
April 2020 (EQIPD)
This issue introduces the Handbook of Experimental Pharmacology, a recent publication by DDNews and the ECNP Congress where EQIPD will be featured.

What we are talking about

Science is Wonderful! brings the world of science, research and innovation to the public. This year, the exhibition will take place fully online from 22 to 24 September to reach out to more European citizens than ever as part of the second edition of the European Research and Innovation Days. IMI is looking for EU-funded projects working in all disciplines and speaking all languages to participate online in the exhibition. If you are convinced that you are up to this exciting e-encounter with many fledgling future scientists, citizens and stakeholders, please fill in the online form by 5 July 2020.
Read more


This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821513. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Parkinson’s UK.

Any related content solely reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.

          Newsletter 4 - June 30, 2020

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
NEURONET project · 14, rue Dicks · Luxembourg 1417 · Luxembourg

Email Marketing Powered by Mailchimp